Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

DRUG(38)
MIXED(34)
PROCEDURE(5)
OTHER(3)
Busulfan (BU)
11 trials
phase_2_3phase_3
nanfang-hospital-southern-medical-university
Cyclophosphamide (CY)
10 trials
phase_2_3phase_3
nanfang-hospital-southern-medical-university
Decitabine
7 trials
phase_2_3
nanfang-hospital-southern-medical-university
ATG
3 trials
not_applicablephase_4
nanfang-hospital-southern-medical-university
Sorafenib
3 trials
phase_2phase_2_3
nanfang-hospital-southern-medical-university
Granulocyte Colony-Stimulating Factor(G-CSF)
3 trials
phase_2_3
nanfang-hospital-southern-medical-university
Non-mesenchymal stem cells
2 trials
phase_2
nanfang-hospital-southern-medical-university
Methotrexate
2 trials
not_applicablephase_4
nanfang-hospital-southern-medical-university

+38 more interventions

46 unique interventions6 categories

Analytics

Trial Phases

Phase 222
Phase 321
Phase 42

Trial Status

Completed8
Recruiting1
Other24

Role Distribution

Principal Investigator33
PI Rate100%

Activity Timeline

Clinical Trials (20)

NCT05453552Phase 2/3Unknown
G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for High-risk MDS Undergoing Allo-HSCT
Allogeneic Hematopoietic Stem Cell TransplantationConditioningMyelodysplastic Syndrome
PrincipalinvestigatorStart date: 2022-07-01
NCT05290545Phase 3Completed
Haplo-PBSC+Cord vs Haplo-PBSC+BM for Hematological Malignancies Undergoing Allo-HSCT
Hematological MalignanciesHematopoietic Stem Cell Transplantation
PrincipalinvestigatorStart date: 2022-02-15
NCT04674345Phase 2/3Unknown
Sorafenib Maintenance for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3 Negative Acute Leukemia
Acute LeukemiaHematopoietic Stem Cell TransplantationRelapse
PrincipalinvestigatorStart date: 2020-12-15
NCT04424147Phase 2Completed
Efficacy and Safety of HVA Regimens as Salvage Treatment in rrAML
HVA RegimenRefractory Acute Myeloid LeukemiaRelapsed Acute Erythroid Leukemia+1 more
PrincipalinvestigatorStart date: 2020-05-27
NCT05404516Phase 2Unknown
Combination of Sorafenib With Standard Therapy in Newly Diagnosed Adult CBF AML
Core Binding Factor Acute Myeloid Leukemia
PrincipalinvestigatorStart date: 2020-01-01
NCT04203108Phase 4Unknown
ATG in HLA-matched Sibling HSCT as GVHD Prophylaxis
Hematopoietic Stem Cell Transplantation
PrincipalinvestigatorStart date: 2019-09-01
NCT03689465Phase 4Unknown
PTCy-ATG vs ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis
Hematopoietic Stem Cell Transplantation
PrincipalinvestigatorStart date: 2018-10-29
NCT03733834Unknown
SD vs. NSD Therapy in Elderly AML
Non-standard TherapyStandard Therapy
PrincipalinvestigatorStart date: 2018-10-08
NCT03665480Phase 2/3Unknown
The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML
Acute Myeloid LeukemiaGranulocyte Colony-stimulating FactorMinimal Residual Disease
PrincipalinvestigatorStart date: 2018-09-04
NCT03620955Unknown
Risk-stratified Therapy Based on Molecular Cytogenetic Aberration and Treatment Response in AML
Cytogenetic AbnormalityMolecular AbnormalityMRD+1 more
PrincipalinvestigatorStart date: 2018-08-10

Showing 10 of 20 trials

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Mary Horowitz, MD

Center for International Blood and Marrow Transplant Research

Related
24 trials

Shared therapeutic areas:

Acute LeukemiaLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukemia, Myeloid, Acute+3 more
Similarity Score4%

Arnon Nagler, MD

Chaim Sheba Medical Center

Related
12 trials

Shared therapeutic areas:

Leukemia, Myeloid, AcuteLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMyelodysplastic Syndromes+2 more
Similarity Score3%

Yves Beguin, MD, PhD

CHU-ULg

Related
7 trials

Shared therapeutic areas:

Hematologic NeoplasmsPrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Myelogenous, Chronic, BCR-ABL Positive+2 more
Similarity Score3%

Beata Holkova, MD

Massey Cancer Center

Related
3 trials

Shared therapeutic areas:

Precursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Myeloid, AcuteLeukemia, Myelogenous, Chronic, BCR-ABL Positive+1 more
Similarity Score3%

Areej El-Jawahri, MD

Massachusetts General Hospital

Related
21 trials

Shared therapeutic areas:

Leukemia, Myeloid, AcuteHematologic NeoplasmsChronic Graft-Versus-Host Disease+1 more
Similarity Score3%

Jorge Cortes, MD

M.D. Anderson Cancer Center

Related
24 trials

Shared therapeutic areas:

Leukemia, Myeloid, AcuteLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMyelodysplastic Syndromes+1 more
Similarity Score3%

Guillermo Garcia-Manero, MD

M.D. Anderson Cancer Center

Related
18 trials

Shared therapeutic areas:

Myelodysplastic SyndromesLeukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-Lymphoma+1 more
Similarity Score3%

Jae Park, MD

Memorial Sloan Kettering Cancer Center

Related
17 trials

Shared therapeutic areas:

Precursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Myeloid, AcuteLymphoma, Large B-Cell, Diffuse
Similarity Score2%

Courtney DiNardo, MD

M.D. Anderson Cancer Center

Related
16 trials

Shared therapeutic areas:

Leukemia, Myeloid, AcuteRefractory Acute Myeloid LeukemiaMyelodysplastic Syndromes
Similarity Score2%

Project Leader

Ono Pharmaceutical Co., Ltd.

Related
47 trials

Shared therapeutic areas:

Acute LeukemiaMyelodysplastic SyndromesPrimary Central Nervous System Lymphoma
Similarity Score2%

Publications (0)

No publications found for this investigator.

Clinical Trials (33)

Showing 20 of 33 trials

NCT05453552Phase 2/3PrincipalInvestigator

G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for High-risk MDS Undergoing Allo-HSCT

Allogeneic Hematopoietic Stem Cell TransplantationConditioningMyelodysplastic Syndrome
Unknown
NCT05290545Phase 3PrincipalInvestigator

Haplo-PBSC+Cord vs Haplo-PBSC+BM for Hematological Malignancies Undergoing Allo-HSCT

Hematological MalignanciesHematopoietic Stem Cell Transplantation
Completed
NCT04674345Phase 2/3PrincipalInvestigator

Sorafenib Maintenance for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3 Negative Acute Leukemia

Acute LeukemiaHematopoietic Stem Cell TransplantationRelapse
Unknown
NCT04424147Phase 2PrincipalInvestigator

Efficacy and Safety of HVA Regimens as Salvage Treatment in rrAML

HVA RegimenRefractory Acute Myeloid LeukemiaRelapsed Acute Erythroid Leukemia+1 more
Completed
NCT05404516Phase 2PrincipalInvestigator

Combination of Sorafenib With Standard Therapy in Newly Diagnosed Adult CBF AML

Core Binding Factor Acute Myeloid Leukemia
Unknown
NCT04203108Phase 4PrincipalInvestigator

ATG in HLA-matched Sibling HSCT as GVHD Prophylaxis

Hematopoietic Stem Cell Transplantation
Unknown
NCT03689465Phase 4PrincipalInvestigator

PTCy-ATG vs ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis

Hematopoietic Stem Cell Transplantation
Unknown
NCT03733834PrincipalInvestigator

SD vs. NSD Therapy in Elderly AML

Non-standard TherapyStandard Therapy
Unknown
NCT03665480Phase 2/3PrincipalInvestigator

The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML

Acute Myeloid LeukemiaGranulocyte Colony-stimulating FactorMinimal Residual Disease
Unknown
NCT03620955PrincipalInvestigator

Risk-stratified Therapy Based on Molecular Cytogenetic Aberration and Treatment Response in AML

Cytogenetic AbnormalityMolecular AbnormalityMRD+1 more
Unknown
NCT03229616Phase 2/3PrincipalInvestigator

BUCY+VP-16 vs BUCY Conditioning Regimen for DLBCL Undergoing Auto-HSCT

Autologous Hematopoietic Stem Cell TransplantationConditioningDiffuse Large B-cell Lymphoma
Unknown
NCT02744742Phase 2/3PrincipalInvestigator

G-CSF+Decitabine+BUCY vs BUCY Conditioning Regimen for RAEB-1, REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT

Allogeneic Hematopoietic Stem Cell TransplantationConditioningMyelodysplastic Syndrome
Completed
NCT02676856Not ApplicablePrincipalInvestigator

Hematopoietic Stem Cell Microtransplantation for in AML

Acute Myeloid Leukemia
Unknown
NCT02670252Phase 3PrincipalInvestigator

BuCY vs TBICY Conditioning Regimen for Standard-risk ALL Undergoing Allo-HSCT

Acute Lymphocytic LeukemiaAllogeneic Hematopoietic Stem Cell TransplantationBusulfan+1 more
Completed
NCT02474290Phase 2/3PrincipalInvestigator

Sorafenib for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3-ITD Positive AML

Acute Myeloid LeukemiaHematopoietic Stem Cell Transplantation
Completed
NCT01765634Phase 2PrincipalInvestigator

Mesenchymal Stem Cells for Treatment of Refractory Acute Graft-versus-host Disease

Acute Graft-versus-host Disease
Unknown
NCT01765660Phase 2PrincipalInvestigator

Mesenchymal Stem Cells for Treatment of Refractory Chronic Graft-versus-host Disease

Chronic Graft-versus-host Disease
Unknown
NCT02487069Not ApplicablePrincipalInvestigator

Allo-HSCT With Alternative Donor in Treatment of Hematologic Malignancy

Acute LeukemiaChronic Myeloid LeukemiaMyelodysplastic Syndrome
Completed
NCT02643589Not ApplicablePrincipalInvestigator

Dose Study of Antithymocyteglobulin in Haploidentical Allogeneic Stem Cell Transplantation

Hematopoietic Stem Cell Transplantation
Unknown
NCT02671708Phase 2/3PrincipalInvestigator

IDA+BUCY vs BUCY Conditioning Regimen for Intermediate-risk AML Undergoing Auto-HSCT

Acute Myeloid LeukemiaAutologous Hematopoietic Stem Cell TransplantationConditioning
Completed